ELAN
Elanco Animal Health Incorporated
Price Chart
Latest Quote
$24.22
+0.83 (+3.55%)
Current Price
| Previous Close | $23.39 |
| Open | $23.84 |
| Day High | $24.50 |
| Day Low | $23.68 |
| Volume | 4,256,731 |
Stock Information
| Shares Outstanding | 499.45M |
| Total Debt | $4.30B |
| Cash Equivalents | $428.00M |
| Revenue | $4.89B |
| Net Income | $-242.00M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $12.10B |
| EPS (TTM) | $-0.50 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $15.97B |
| Sales | $4.89B |
| Income | $-242.00M |
| Book/sh | $13.02 |
| Cash/sh | $0.86 |
| Employees | 9K |
Financial Ratios
| Quick Ratio | 0.95 |
| Current Ratio | 2.16 |
| Debt/Eq | 66.15 |
| EPS Growth TTM | -14.90% |
Returns & Margins
| ROA | 1.47% |
| ROE | -3.77% |
| Gross Margin | 55.06% |
| Operating Margin | 12.33% |
| Profit Margin | -4.95% |
Ownership
| Insider Ownership | 1.22% |
| Institutional Ownership | 111.35% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 20.43 |
| PEG | 4.04 |
| P/S | 2.47 |
| P/B | 1.86 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $29.86 |
Technical Indicators
| SMA20 | $23.65 |
| SMA50 | $22.98 |
| SMA200 | $22.62 |
| RSI | 52.30 |
| ATR | 1.1179 |
| Shares Float | 494.84M |
| Short Float | 10.55% |
| Short Ratio | 4.45 |
| Volatility | 1.70 |
| Rel Volume | 1.63 |
Performance History
| Week | +0.71% |
| Month | +22.32% |
| Quarter | -3.58% |
| 6 Months | +7.69% |
| YTD | +7.55% |
| Year | +77.96% |
| 3 Years | +139.80% |
| 5 Years | -28.13% |
| 10 Years | -32.72% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $24.22 | 10,244,000 |
| 2026-06-17 | $23.39 | 6,540,500 |
| 2026-06-16 | $24.23 | 3,681,700 |
| 2026-06-15 | $24.29 | 4,476,700 |
| 2026-06-12 | $24.17 | 4,512,100 |
| 2026-06-11 | $24.05 | 4,735,400 |
| 2026-06-10 | $22.87 | 7,947,600 |
| 2026-06-09 | $24.50 | 5,131,200 |
| 2026-06-08 | $23.68 | 5,272,600 |
| 2026-06-05 | $23.63 | 4,215,300 |
| 2026-06-04 | $24.71 | 7,598,900 |
| 2026-06-03 | $24.57 | 8,115,500 |
| 2026-06-02 | $23.63 | 3,717,700 |
| 2026-06-01 | $23.67 | 5,324,900 |
| 2026-05-29 | $23.85 | 10,587,400 |
| 2026-05-28 | $23.98 | 6,425,800 |
| 2026-05-27 | $23.69 | 8,281,000 |
| 2026-05-26 | $22.82 | 7,148,300 |
| 2026-05-22 | $21.73 | 5,828,900 |
| 2026-05-21 | $21.32 | 6,126,700 |
| 2026-05-20 | $20.85 | 8,000,700 |
| 2026-05-19 | $19.80 | 7,919,900 |
About Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
đ° Latest News
1 Profitable Stock to Target This Week and 2 We Avoid
StockStory âĸ 2026-06-16T12:09:04Z
2 Cash-Producing Stocks on Our Buy List and 1 That Underwhelm
StockStory âĸ 2026-06-12T09:50:56Z
Is It Too Late To Consider Elanco Animal Health (ELAN) After Its Strong 1 Year Rally?
Simply Wall St. âĸ 2026-06-05T06:07:19Z
Jim Cramer Says He Feels 'Something Not Well' At Zoetis, Names A Rival As His Pick
Benzinga âĸ 2026-06-04T21:30:37Z
A Flesh-Eating Fly Adds to the Beef Industryâs List of Problems
Barrons.com âĸ 2026-06-04T20:21:00Z
Beef Supply Resilient, Screwworm or No, Elanco CEO Says
The Wall Street Journal âĸ 2026-06-04T17:47:30Z
A Look At Elanco (ELAN) Valuation After Early Befrena Launch And Renewed Investor Optimism
Simply Wall St. âĸ 2026-06-01T21:14:13Z
3 of Wall Streetâs Favorite Stocks We Think Twice About
StockStory âĸ 2026-06-01T19:20:51Z
Elanco (ELAN) Is Up 9.8% After Launching Befrena, Its Second USDA-Approved Pet Biologic
Simply Wall St. âĸ 2026-06-01T18:12:37Z
3 Healthcare Stocks We Keep Off Our Radar
StockStory âĸ 2026-05-28T16:30:27Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,985,000,000 | $1,868,000,000 | $1,785,000,000 | $1,759,000,000 |
| Cost Of Revenue | $2,122,000,000 | $2,003,000,000 | $1,931,000,000 | $1,913,000,000 |
| Total Revenue | $4,715,000,000 | $4,439,000,000 | $4,417,000,000 | $4,411,000,000 |
| Operating Revenue | $4,715,000,000 | $4,439,000,000 | $4,417,000,000 | $4,411,000,000 |
| Expenses | ||||
| Interest Expense | $220,000,000 | $235,000,000 | $277,000,000 | $241,000,000 |
| Total Expenses | $4,463,000,000 | $4,188,000,000 | $4,091,000,000 | $4,027,000,000 |
| Other Income Expense | $-256,000,000 | $472,000,000 | $-1,244,000,000 | $-215,000,000 |
| Other Non Operating Income Expenses | $-19,000,000 | $-18,000,000 | $-75,000,000 | $-32,000,000 |
| Net Non Operating Interest Income Expense | $-220,000,000 | $-235,000,000 | $-277,000,000 | $-241,000,000 |
| Interest Expense Non Operating | $220,000,000 | $235,000,000 | $277,000,000 | $241,000,000 |
| Operating Expense | $2,341,000,000 | $2,185,000,000 | $2,160,000,000 | $2,114,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-232,000,000 | $338,000,000 | $-1,231,000,000 | $-78,000,000 |
| Net Interest Income | $-220,000,000 | $-235,000,000 | $-277,000,000 | $-241,000,000 |
| Normalized Income | $-44,770,000 | $-1,570,000 | $-307,490,000 | $66,570,000 |
| Net Income From Continuing And Discontinued Operation | $-232,000,000 | $338,000,000 | $-1,231,000,000 | $-78,000,000 |
| Net Income Common Stockholders | $-232,000,000 | $338,000,000 | $-1,231,000,000 | $-78,000,000 |
| Net Income | $-232,000,000 | $338,000,000 | $-1,231,000,000 | $-78,000,000 |
| Net Income Including Noncontrolling Interests | $-232,000,000 | $338,000,000 | $-1,231,000,000 | $-78,000,000 |
| Net Income Continuous Operations | $-232,000,000 | $338,000,000 | $-1,231,000,000 | $-78,000,000 |
| Pretax Income | $-224,000,000 | $488,000,000 | $-1,195,000,000 | $-72,000,000 |
| Special Income Charges | $-237,000,000 | $490,000,000 | $-1,169,000,000 | $-183,000,000 |
| Operating Income | $252,000,000 | $251,000,000 | $326,000,000 | $384,000,000 |
| Depreciation Amortization Depletion Income Statement | $543,000,000 | $527,000,000 | $548,000,000 | $528,000,000 |
| Depreciation And Amortization In Income Statement | $543,000,000 | $527,000,000 | $548,000,000 | $528,000,000 |
| Amortization Of Intangibles Income Statement | $543,000,000 | $527,000,000 | $548,000,000 | $528,000,000 |
| Gross Profit | $2,593,000,000 | $2,436,000,000 | $2,486,000,000 | $2,498,000,000 |
| Per Share | ||||
| Diluted EPS | $-0.47 | $0.68 | $-2.50 | $-0.15 |
| Basic EPS | $-0.47 | $0.68 | $-2.50 | $-0.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $-49,770,000 | $150,430,000 | $-245,490,000 | $-38,430,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $913,000,000 | $895,000,000 | $945,000,000 | $1,034,000,000 |
| Total Unusual Items | $-237,000,000 | $490,000,000 | $-1,169,000,000 | $-183,000,000 |
| Total Unusual Items Excluding Goodwill | $-237,000,000 | $490,000,000 | $-1,169,000,000 | $-183,000,000 |
| Reconciled Depreciation | $680,000,000 | $662,000,000 | $694,000,000 | $682,000,000 |
| EBITDA (Bullshit earnings) | $676,000,000 | $1,385,000,000 | $-224,000,000 | $851,000,000 |
| EBIT | $-4,000,000 | $723,000,000 | $-918,000,000 | $169,000,000 |
| Diluted Average Shares | $496,400,000 | $497,300,000 | $492,300,000 | $488,300,000 |
| Basic Average Shares | $496,400,000 | $494,000,000 | $492,300,000 | $488,300,000 |
| Diluted NI Availto Com Stockholders | $-232,000,000 | $338,000,000 | $-1,231,000,000 | $-78,000,000 |
| Tax Provision | $8,000,000 | $150,000,000 | $36,000,000 | $6,000,000 |
| Gain On Sale Of Business | $0 | $640,000,000 | $0 | $0 |
| Other Special Charges | $8,000,000 | $7,000,000 | $2,000,000 | $4,000,000 |
| Write Off | $39,000,000 | - | - | - |
| Impairment Of Capital Assets | $71,000,000 | $81,000,000 | $1,074,000,000 | $81,000,000 |
| Restructuring And Mergern Acquisition | $119,000,000 | $62,000,000 | $93,000,000 | $98,000,000 |
| Amortization | $543,000,000 | $527,000,000 | $548,000,000 | $528,000,000 |
| Research And Development | $368,000,000 | $344,000,000 | $327,000,000 | $321,000,000 |
| Selling General And Administration | $1,430,000,000 | $1,314,000,000 | $1,285,000,000 | $1,265,000,000 |
| Gain On Sale Of Ppe | - | - | - | $0 |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,640,000,000 | $-1,999,000,000 | $-3,365,000,000 | $-3,546,000,000 |
| Total Assets | $13,358,000,000 | $12,614,000,000 | $14,362,000,000 | $15,491,000,000 |
| Total Non Current Assets | $9,900,000,000 | $9,399,000,000 | $10,955,000,000 | $12,212,000,000 |
| Other Non Current Assets | $304,000,000 | $311,000,000 | $341,000,000 | $378,000,000 |
| Goodwill And Other Intangible Assets | $8,187,000,000 | $8,095,000,000 | $9,588,000,000 | $10,835,000,000 |
| Other Intangible Assets | $3,408,000,000 | $3,681,000,000 | $4,494,000,000 | $4,842,000,000 |
| Current Assets | $3,458,000,000 | $3,215,000,000 | $3,407,000,000 | $3,279,000,000 |
| Other Current Assets | $236,000,000 | $287,000,000 | $310,000,000 | $394,000,000 |
| Inventory | $1,737,000,000 | $1,574,000,000 | $1,735,000,000 | $1,538,000,000 |
| Receivables | $940,000,000 | $886,000,000 | $1,010,000,000 | $1,002,000,000 |
| Other Receivables | $67,000,000 | $81,000,000 | $168,000,000 | $205,000,000 |
| Accounts Receivable | $873,000,000 | $805,000,000 | $842,000,000 | $797,000,000 |
| Allowance For Doubtful Accounts Receivable | $-17,000,000 | $-13,000,000 | $-18,000,000 | $-13,000,000 |
| Gross Accounts Receivable | $890,000,000 | $818,000,000 | $860,000,000 | $810,000,000 |
| Cash Cash Equivalents And Short Term Investments | $545,000,000 | $468,000,000 | $352,000,000 | $345,000,000 |
| Cash And Cash Equivalents | $545,000,000 | $468,000,000 | $352,000,000 | $345,000,000 |
| Restricted Cash | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $3,472,000,000 | $3,853,000,000 | $5,422,000,000 | $5,491,000,000 |
| Total Debt | $4,017,000,000 | $4,321,000,000 | $5,774,000,000 | $5,836,000,000 |
| Long Term Debt And Capital Lease Obligation | $3,943,000,000 | $4,277,000,000 | $5,736,000,000 | $5,448,000,000 |
| Long Term Debt | $3,943,000,000 | $4,277,000,000 | $5,736,000,000 | $5,448,000,000 |
| Current Debt And Capital Lease Obligation | $74,000,000 | $44,000,000 | $38,000,000 | $388,000,000 |
| Current Debt | $74,000,000 | $44,000,000 | $38,000,000 | $388,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $6,811,000,000 | $6,518,000,000 | $8,139,000,000 | $8,202,000,000 |
| Total Non Current Liabilities Net Minority Interest | $5,214,000,000 | $5,203,000,000 | $6,898,000,000 | $6,500,000,000 |
| Other Non Current Liabilities | $427,000,000 | $302,000,000 | $411,000,000 | $229,000,000 |
| Liabilities Heldfor Sale Non Current | $304,000,000 | $0 | - | - |
| Non Current Deferred Liabilities | $382,000,000 | $449,000,000 | $567,000,000 | $662,000,000 |
| Non Current Deferred Taxes Liabilities | $382,000,000 | $449,000,000 | $567,000,000 | $662,000,000 |
| Current Liabilities | $1,597,000,000 | $1,315,000,000 | $1,241,000,000 | $1,702,000,000 |
| Other Current Liabilities | $533,000,000 | $466,000,000 | $409,000,000 | $454,000,000 |
| Current Deferred Liabilities | $416,000,000 | $332,000,000 | $367,000,000 | $324,000,000 |
| Payables And Accrued Expenses | $368,000,000 | $296,000,000 | $270,000,000 | $390,000,000 |
| Payables | $368,000,000 | $296,000,000 | $270,000,000 | $390,000,000 |
| Accounts Payable | $368,000,000 | $296,000,000 | $270,000,000 | $390,000,000 |
| Equity | ||||
| Common Stock Equity | $6,547,000,000 | $6,096,000,000 | $6,223,000,000 | $7,289,000,000 |
| Total Equity Gross Minority Interest | $6,547,000,000 | $6,096,000,000 | $6,223,000,000 | $7,289,000,000 |
| Stockholders Equity | $6,547,000,000 | $6,096,000,000 | $6,223,000,000 | $7,289,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-141,000,000 | $-771,000,000 | $-266,000,000 | $-392,000,000 |
| Other Equity Adjustments | $-141,000,000 | $-771,000,000 | $-266,000,000 | $-392,000,000 |
| Retained Earnings | $-2,182,000,000 | $-1,950,000,000 | $-2,288,000,000 | $-1,057,000,000 |
| Other | ||||
| Ordinary Shares Number | $496,975,154 | $494,445,839 | $492,845,216 | $474,237,738 |
| Share Issued | $496,975,154 | $494,445,839 | $492,845,216 | $474,237,738 |
| Tangible Book Value | $-1,640,000,000 | $-1,999,000,000 | $-3,365,000,000 | $-3,546,000,000 |
| Invested Capital | $10,564,000,000 | $10,417,000,000 | $11,997,000,000 | $13,125,000,000 |
| Working Capital | $1,861,000,000 | $1,900,000,000 | $2,166,000,000 | $1,577,000,000 |
| Total Capitalization | $10,490,000,000 | $10,373,000,000 | $11,959,000,000 | $12,737,000,000 |
| Additional Paid In Capital | $8,870,000,000 | $8,817,000,000 | $8,777,000,000 | $8,738,000,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | - | $0 |
| Employee Benefits | $158,000,000 | $175,000,000 | $184,000,000 | $161,000,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $158,000,000 | $175,000,000 | $184,000,000 | $161,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $206,000,000 | $177,000,000 | $157,000,000 | $146,000,000 |
| Goodwill | $4,779,000,000 | $4,414,000,000 | $5,094,000,000 | $5,993,000,000 |
| Net PPE | $1,409,000,000 | $993,000,000 | $1,026,000,000 | $999,000,000 |
| Accumulated Depreciation | $-952,000,000 | $-858,000,000 | $-815,000,000 | $-723,000,000 |
| Gross PPE | $2,361,000,000 | $1,851,000,000 | $1,841,000,000 | $1,722,000,000 |
| Construction In Progress | $268,000,000 | $221,000,000 | $186,000,000 | $163,000,000 |
| Other Properties | $1,329,000,000 | $990,000,000 | $985,000,000 | $941,000,000 |
| Buildings And Improvements | $698,000,000 | $600,000,000 | $630,000,000 | $578,000,000 |
| Land And Improvements | $66,000,000 | $40,000,000 | $40,000,000 | $40,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-75,000,000 | $-61,000,000 | $-64,000,000 | $-58,000,000 |
| Finished Goods | $871,000,000 | $754,000,000 | $857,000,000 | $783,000,000 |
| Work In Process | $837,000,000 | $783,000,000 | $814,000,000 | $683,000,000 |
| Raw Materials | $104,000,000 | $98,000,000 | $128,000,000 | $130,000,000 |
| Machinery Furniture Equipment | - | - | - | $941,000,000 |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $284,000,000 | $394,000,000 | $131,000,000 | $268,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $560,000,000 | $541,000,000 | $271,000,000 | $452,000,000 |
| Cash Flow From Continuing Operating Activities | $560,000,000 | $541,000,000 | $271,000,000 | $452,000,000 |
| Operating Gains Losses | - | $-640,000,000 | - | $20,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-276,000,000 | $-147,000,000 | $-140,000,000 | $-184,000,000 |
| Investing Cash Flow | $-279,000,000 | $1,158,000,000 | $-169,000,000 | $-179,000,000 |
| Cash Flow From Continuing Investing Activities | $-279,000,000 | $1,158,000,000 | $-169,000,000 | $-179,000,000 |
| Net Other Investing Changes | $-12,000,000 | $-14,000,000 | $-10,000,000 | $-8,000,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-275,000,000 | $-1,492,000,000 | $-83,000,000 | $-549,000,000 |
| Cash Flow From Continuing Financing Activities | $-275,000,000 | $-1,492,000,000 | $-83,000,000 | $-549,000,000 |
| Net Other Financing Charges | $288,000,000 | $-17,000,000 | $-6,000,000 | $-47,000,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-2,919,000,000 | $-2,045,000,000 | $-677,000,000 | $-1,490,000,000 |
| Issuance Of Debt | $2,356,000,000 | $570,000,000 | $600,000,000 | $988,000,000 |
| End Cash Position | $545,000,000 | $468,000,000 | $352,000,000 | $345,000,000 |
| Beginning Cash Position | $468,000,000 | $352,000,000 | $345,000,000 | $638,000,000 |
| Effect Of Exchange Rate Changes | $71,000,000 | $-91,000,000 | $-12,000,000 | $-17,000,000 |
| Changes In Cash | $6,000,000 | $207,000,000 | $19,000,000 | $-276,000,000 |
| Net Issuance Payments Of Debt | $-563,000,000 | $-1,475,000,000 | $-77,000,000 | $-502,000,000 |
| Net Long Term Debt Issuance | $-563,000,000 | $-1,475,000,000 | $-77,000,000 | $-502,000,000 |
| Long Term Debt Payments | $-2,919,000,000 | $-2,045,000,000 | $-677,000,000 | $-1,490,000,000 |
| Long Term Debt Issuance | $2,356,000,000 | $570,000,000 | $600,000,000 | $988,000,000 |
| Net Business Purchase And Sale | $9,000,000 | $1,319,000,000 | $-19,000,000 | $13,000,000 |
| Sale Of Business | $9,000,000 | $1,360,000,000 | $0 | $13,000,000 |
| Purchase Of Business | $0 | $-41,000,000 | $-19,000,000 | $0 |
| Net PPE Purchase And Sale | $-276,000,000 | $-147,000,000 | $-140,000,000 | $-171,000,000 |
| Purchase Of PPE | $-276,000,000 | $-147,000,000 | $-140,000,000 | $-171,000,000 |
| Change In Working Capital | $99,000,000 | $149,000,000 | $-300,000,000 | $-462,000,000 |
| Change In Other Current Assets | $21,000,000 | $11,000,000 | $-6,000,000 | $-109,000,000 |
| Change In Payables And Accrued Expense | $147,000,000 | $82,000,000 | $-94,000,000 | $-98,000,000 |
| Change In Payable | $147,000,000 | $82,000,000 | $-94,000,000 | $-98,000,000 |
| Change In Account Payable | $147,000,000 | $82,000,000 | $-94,000,000 | $-98,000,000 |
| Change In Inventory | $-57,000,000 | $44,000,000 | $-160,000,000 | $-269,000,000 |
| Change In Receivables | $-12,000,000 | $12,000,000 | $-40,000,000 | $14,000,000 |
| Other Non Cash Items | $8,000,000 | $8,000,000 | $68,000,000 | $207,000,000 |
| Stock Based Compensation | $68,000,000 | $55,000,000 | $46,000,000 | $59,000,000 |
| Asset Impairment Charge | $71,000,000 | $81,000,000 | $1,074,000,000 | $81,000,000 |
| Deferred Tax | $-134,000,000 | $-112,000,000 | $-80,000,000 | $-57,000,000 |
| Deferred Income Tax | $-134,000,000 | $-112,000,000 | $-80,000,000 | $-57,000,000 |
| Depreciation Amortization Depletion | $680,000,000 | $662,000,000 | $694,000,000 | $682,000,000 |
| Depreciation And Amortization | $680,000,000 | $662,000,000 | $694,000,000 | $682,000,000 |
| Gain Loss On Sale Of Business | $0 | $-640,000,000 | $0 | $0 |
| Net Income From Continuing Operations | $-232,000,000 | $338,000,000 | $-1,231,000,000 | $-78,000,000 |
| Net Intangibles Purchase And Sale | - | $-14,000,000 | $-14,000,000 | $-13,000,000 |
| Purchase Of Intangibles | - | $-14,000,000 | $-14,000,000 | $-13,000,000 |
| Net Short Term Debt Issuance | - | - | - | $-250,000,000 |
| Short Term Debt Payments | - | - | - | $-813,000,000 |
| Short Term Debt Issuance | - | - | - | $563,000,000 |
| Sale Of PPE | - | - | - | $0 |
| Change In Other Working Capital | - | - | - | - |
Fetched: 2026-06-14